Suchen
Neurosense Therapeutics Ltd
NRSNZur Watchlist hinzufügen
0.723USD
+0.003+0.42%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
25.56MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Neurosense Therapeutics Ltd Unternehmen
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Neurosense Therapeutics Ltd Informationen
BörsenkürzelNRSN
Name des UnternehmensNeurosense Therapeutics Ltd
IPO-datumDec 09, 2021
CEOBen-Noon (Alon)
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeDec 09
Addresse11 Hamenofim St.
StadtHERZLIYA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl4672562
Telefon97297996183
Websitehttps://www.neurosense-tx.com/
BörsenkürzelNRSN
IPO-datumDec 09, 2021
CEOBen-Noon (Alon)
Führungskräfte von Neurosense Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Neurosense Therapeutics Ltd?
Die fünf größten Anteilseigner von Neurosense Therapeutics Ltd sind: Mr. Alon Ben-Noon
Wie viele Institutionen halten Anteile an Neurosense Therapeutics Ltd (NRSN)?
Mit Stand vom 2026Q1 halten 33 Institutionen Anteile an Neurosense Therapeutics Ltd, mit einem Gesamtmarktwert von etwa 367.79K, was 1.04% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2009158.00 gestiegen.